Clinical experience of low-dose PTCY combined with ATG in preventing graft versus host disease after hematopoietic stem cell transplantation in children with β-thalassemia
10.3760/cma.j.cn421203-20240912-00191
- VernacularTitle:低剂量PTCY联合ATG方案预防儿童β地中海贫血HSCT后GVHD临床经验
- Author:
Jingyuan LU
1
;
Yanxin CHEN
1
;
Xiuli HONG
1
;
Jie CHEN
1
;
Yanhong ZHUANG
1
;
Quanyi LU
1
Author Information
1. 厦门大学附属中山医院血液科，厦门 361005
- Publication Type:Journal Article
- Keywords:
Hematopoietic stem cell transplantation;
Child;
β-Thalassemia;
Graft versus host disease
- From:
Chinese Journal of Organ Transplantation
2025;46(5):358-364
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of low-dose post-transplant cyclophosphamide (PTCY) combined with anti-thymocyte globulin (ATG) in preventing graft-versus-host disease (GVHD) in children with β-thalassemia after hematopoietic stem-cell transplantation (HSCT).Method:A retrospective analysis was conducted on 42 children with transfusion-dependent β-thalassemia who underwent HSCT at Zhongshan Hospital, Xiamen University between March 2019 and June 2023. Based on donor source, recipients were grouped into the haploidentical donor group (Haplo-RD, 10 cases) and the unrelated donor group (UD, 32 cases). The UD group was further subdivided into HLA 8/10 matched (2 cases), HLA 9/10 matched (15 cases), and fully HLA-matched (15 cases). The conditioning regimen included fludarabine, busulfan, cyclophosphamide, and thiotepa. GVHD prophylaxis consisted of ATG (4.5 mg/kg), cyclophosphamide (25 mg/kg for 2 days), cyclosporine A (CsA), and mycophenolate mofetil (MMF). Engraftment, GVHD incidence, survival, mortality, and virus reactivation rates were evaluated.Result:The median age was 6 years (range, 2~12). All patients achieved hematopoietic reconstitution. The median times to neutrophil and platelet engraftment were 11 days (range, 10~15) days and 12 days (range, 6~31), respectively. All recipients had >95% peripheral blood STR chimerism by day 30. Grade Ⅲ~Ⅳ acute GVHD occurred in 3 recipients (7.14%), and chronic GVHD occurred in 5 recipients (11.90%) -1 case extensive, 4 cases limited. Both overall survival (OS) and disease-free survival (DFS) were 92.86%. All children in the Haplo-RD group achieved DFS. Eight patients developed cytomegalovirus (CMV) viremia (no CMV disease), with a reactivation rate of 19.05%, and 9 recipients had BK virus-related urinary tract infections (6 cases in the UD group and 3 cases in the Haplo-RD group), for a total incidence of 21.43%.Conclusion:The combination of low-dose PTCY and ATG is a safe and effective strategy to prevent GVHD following haploidentical or unrelated donor HSCT in pediatric β-thalassemia. It is associated with reduced infection and viral reactivation post-transplant and contributes to high survival rates.
